The popularity of Sildenafil initially drove a period of growth for pharma, however recent shifts present a complicated scenario for shareholders. Off-patent versions are reducing earnings, and ongoing patent challenges add further difficulty to the equation. While certain companies may still benefit from adjacent products, the overall trajector… Read More